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Abstract 27 
Diabetes is the major cause of end stage renal disease globally, and novel treatments 28 
are urgently needed. Current therapeutic approaches for diabetic nephropathy are 29 
focusing on the inhibition of the renin angiotensin aldosterone system, on glycaemic 30 
and lipid control, and life style changes. In this review we will highlight new molecular 31 
insights in our understanding of the initiation and progression of diabetic nephropathy 32 
including glomerular insulin resistance, dysregulation of cellular substrate utilisation, 33 
podocyte-endothelial communication and inhibition of tubular sodium coupled glucose 34 
reabsorption. We believe these mechanisms offer new therapeutic targets that can be 35 
exploited to develop important renoprotective treatments for diabetic nephropathy over 36 
the next decade.  37 
  38 
 3 
INTRODUCTION 39 
Diabetes mellitus is a metabolic disorder associated with chronic micro- and 40 
macrovascular complications. One of the most feared chronic microvascular 41 
complications is diabetic nephropathy (DN), currently the leading cause of end-stage 42 
renal disease (ESRD) in the Western world. Strikingly, 40-45% of patients with type-1 43 
diabetes (T1D) develop DN and reach ESRD or die before its onset. Moreover, 44 
clinicians face a ~30% prevalence of patients with type-2 diabetes (T2D) and DN, with 45 
45% of patients currently on dialysis having a primary diagnosis of diabetes, a 46 
population also at high risk of developing cardiovascular disease [1]. 47 
 48 
An early sign of DN is an increased amount of urinary protein, manifested by 49 
“albuminuria”, which correlates with, and can predict, the progression of renal damage. 50 
Albuminuria arises from defects in the permeability of the glomerular filtration barrier 51 
consisting of glomerular endothelial cells (GECs) separated from specialized epithelia, 52 
called podocytes, by the glomerular basement membrane (GBM)[1]. Podocytes have 53 
extensive inter-digitating foot processes connected together by a slit diaphragm 54 
composed of proteins including nephrin and neph1, which interact with cytoplasmic 55 
adaptor and signalling proteins (PI3-Kinase, CD2AP, AKT, podocin). Nephrin is also 56 
linked with the podocyte actin cytoskeleton; the protein tyrosine kinase Fyn promotes 57 
nephrin phosphorylation which enhances its interaction with PI3-Kinase and PI3K-58 
dependent phosphorylation of AKT and subsequently increases Rac1 activity, leading 59 
to modification of the actin cytoskeleton with maintenance of a normal podocyte 60 
anatomical structure and function [2, 3]. The structure and integrity of the glomerulus 61 
is also maintained by a complex local autocrine/paracrine network between the 62 
podocyte and the GECs consisting of vascular growth factors and vasoactive peptides 63 
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which is disrupted in DN [4]. The GECs are highly fenestrated with a unique 64 
ultrastructure lacking fenestrae diaphragms which facilitate water and small solutes 65 
permeability [5]. GECs are covered by a glycocalyx consisting mainly of proteoglycans 66 
which include core proteins such as syndecan and attached glycosaminoglycan side 67 
chains which appear to be important in regulating the permeability of the glomerulus 68 
[6]. 69 
 70 
Animal and human studies have established that the metabolic and haemodynamic 71 
changes that occur in diabetes lead to ultrastructural alterations of the glomerular 72 
filtration barrier, including podocyte foot process fusion and detachment, GBM 73 
thickening, a reduced endothelial cell glycocalyx, mesangial extracellular matrix 74 
accumulation and glomerulosclerosis (Figure 1). These structural glomerular changes 75 
correlate with increasing albuminuria which has been proposed to be a marker of 76 
generalised systemic vascular dysfunction by the “Steno hypothesis” [7] and could 77 
represent a common pathogenetic mechanism for renal and extra-renal chronic 78 
vascular complications in diabetes [1]. 79 
 80 
Over the last 5-10 years our understanding of the molecular and cellular pathways by 81 
which diabetic kidney disease results in damage to the glomerular filtration barrier has 82 
increased. In this review, we will outline recent advances in glomerular insulin 83 
signalling, oxidative and endoplasmic reticulum (ER) stress and podocyte-endothelial 84 
communication that have revealed new exciting therapeutic directions for DN. 85 
 86 
 87 
Insulin resistance as a mechanism for the predisposition of DN 88 
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Insulin is a metabolic hormone which not only regulates glucose and the metabolism 89 
of other substrates but also directly modulates the biology of specific cells in a variety 90 
of tissues. In both T1D and T2D patients, the ability of insulin to elicit cellular responses 91 
is impaired, a concept termed “cellular insulin resistance”, and is associated with DN 92 
[8]. Insulin resistance correlates with the development of microalbuminuria both in T1D 93 
and T2D patients and patients with T1D with DN are more likely to have a strong family 94 
history of insulin resistance when compared with those without DN [9]. Insulin 95 
resistance has been implicated in the development of glomerular hypertension and 96 
hyperfiltration [10], seen in the initial phase of diabetic kidney disease [11]. 97 
Furthermore, in both T1D and T2D patients, insulin resistance per se contributes to 98 
higher salt sensitivity, which closely associates with increases in blood pressure, 99 
albuminuria, and a decline in renal function [12, 13]. 100 
 101 
Within the kidney many different cell types are insulin sensitive and express functional 102 
insulin receptors [14-17]. Furthermore, transgenic mouse models have revealed that 103 
inducing insulin resistance in different nephron compartments results in a variety of 104 
unfavourable renal phenotypes. In the glomerulus, approximately a decade ago it was 105 
discovered that human podocytes respond to insulin [14], and express the hallmark 106 
components of insulin sensitive cells including the insulin receptor, and key glucose 107 
transporters including GLUT4 and GLUT1. To elucidate the biological significance of 108 
insulin signalling in these cells, podocyte specific insulin receptor knockout mice were 109 
generated [18]. These animals developed albuminuria and a number of features of 110 
DN, including increased matrix production, glomerulosclerosis, and GBM thickening, 111 
but all in normoglycaemic conditions, suggesting that insulin resistance of this cell per 112 
se may be an important driver in glomerular diseases. Insulin signaling is important in 113 
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other parts of the nephron. Deletion of the insulin receptor In tubular epithelial cells 114 
widespread led to reduced natriuresis and hypertension [16]. Recent studies have 115 
begun to dissect out the precise function of the insulin receptor in specific tubular 116 
segments. These experiments revealed that loss of the insulin receptor in proximal 117 
tubules results in gluconeogenesis [19] while deletion in collecting ducts increased 118 
natriuresis and lowered blood pressure [20].  119 
 120 
 121 
Diabetes provides an ideal environment consisting of increased adiposity, 122 
hyperglycaemia, and inflammation which are all important players in promoting 123 
podocyte insulin resistance and glomerular dysfunction [17](Table 1). A recent study 124 
has identified SMAD3 within the inflammation/ fibrosis pathway as an important 125 
modulator of podocyte insulin sensitivity in a model of obesity related DN [21]. In this 126 
work, mice fed a high fat diet exhibited an increase in kidney and podocyte SMAD3 127 
expression levels which resulted in a severely fibrotic kidney; in these conditions 128 
SMAD3 knockout animals were protected from kidney damage and fibrosis. In parallel, 129 
fatty acid palmitate induces a SMAD3-mediated podocyte insulin resistance paralleled 130 
by mitochondrial dysfunction in vitro. These responses were exaggerated when 131 
animals became albuminuric, and could be rescued by SMAD3 blockade and 132 
restoration of podocyte insulin signalling [21]. Other studies have demonstrated that 133 
both Nucleotide-binding oligomerization domain containing protein 2 (NOD2)[22] and 134 
Toll-like receptor (TLR)[23] mediated-inflammation have an adverse effect on 135 
podocyte survival, insulin action, and glomerular permeability to protein. Decreased 136 
circulating adiponectin [24, 25], increased free fatty acids (FFA) levels  [26], and 137 
defects in insulin action promote glomerular cells and podocyte dysfunction, and 138 
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albuminuria [27, 28]. Epigenetic mechanisms may also be important in determining 139 
insulin resistance [29]. This concept has not been studied in great detail to-date, but 140 
Kumar and colleagues have shown that insulin resistance induced by palmitate in 141 
human urinary podocyte cell lines is associated with an increase in histone H3K36me2 142 
and reduced H3K27me3 on the promoter region of FOXO1, a regulator of 143 
gluconeogenic genes. This effect was long-lasting and persisted even after the 144 
normalisation of palmitate levels [30]. 145 
 146 
 147 
Glomerular insulin resistance, endoplasmic reticulum (ER) stress and 148 
autophagy in diabetic glomerulopathy 149 
There are many consequences of insulin resistance within glomeruli, which are likely 150 
to contribute to the progression of DN. One key mechanism is changes to the 151 
mitochondria and the closely connected ER [31]. Mitochondrial metabolic overload 152 
results in increased cellular oxidative stress and ER-stress which leads to the 153 
activation of unfolded protein response (UPR)[32]. UPR is a positive cellular response 154 
that in its early phase either refolds accumulated unfolded proteins, or degrades 155 
unfolded protein by the ubiquitin-proteasome pathway. Misfolded proteins are 156 
detected by the ER membrane stress sensors protein kinase RNA-like ER kinase 157 
(PERK), inositol-requiring protein 1α (IRE1α) and activating transcription factor 6α 158 
(ATF6α) and its activator X-box binding protein-1 (XBP-1), which, in turn, activates 159 
several signalling events and trigger a compensatory response to prevent further 160 
accumulation of misfolded protein. However, when the unfolded protein and cellular 161 
damage exceeds a threshold, chronic and unresolved stress results in a change from 162 
an adaptive to pro-apoptotic responses [32]. 163 
 8 
 164 
There is some evidence that glucose/oxidative stress-mediated ER stress plays a role 165 
in chronic vascular complications in DN [33]. Hyperglycemia, or increased glycation of 166 
proteins have been shown to mediate apoptosis partly through increases in ER stress 167 
in cultured murine podocytes [34, 35]. Activation of the UPR has also been observed 168 
in mouse glomerular mesangial cells exposed to glucose and glucosamine [36], and 169 
in kidneys from diabetic rats administered streptozotocin for 16 weeks [37]. Microarray 170 
analysis of human biopsies from patients with established DN showed that UPR genes 171 
were upregulated proportionally to the severity of diabetic renal lesions [38]. Finally, 172 
recent experimental evidence has demonstrated that pharmacological inhibition of ER 173 
stress and stabilization of the UPR is beneficial in diabetic glomerulopathy [39]. 174 
 175 
Two studies have used transgenic mice to link podocyte insulin resistance with 176 
mitochondrial function and ER stress. Ising and colleagues generated a mouse model 177 
of podocyte mitochondrial dysfunction by specifically knocking out a key molecule in 178 
this cell involved in mitochondrial fusion called prohibitin-2 [40]. This caused a severe 179 
phenotype including glomerulosclerosis, renal failure and death at approximately a 180 
month of age. They then went on to inhibit both the insulin receptor and IGF-1 receptor 181 
(IGF1R) contemporaneously with podocyte-specific knockdown of prohibitin-2. 182 
Inhibiting the insulin receptor alone, or in combination with the IGF1R was partially 183 
protective and resulted in a significantly longer life span of the mice [40]. This suggests 184 
that insulin resistance could reflect a “protective” resetting of cellular substrate 185 
utilisation to shield from excess substrate flow to mitochondria with “impaired” 186 
respiratory capabilities. In another study, Madhusudhan et al. have elegantly shown 187 
that under diabetic conditions ER adaptive mechanisms are impaired in the podocyte 188 
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and that this is exacerbated when the cell is rendered more insulin resistant. Studying 189 
human and murine DN they discovered that nephropathy was associated with 190 
alterations in the UPR with impairment of the nuclear translocation of XBP-1. Genetic 191 
ablation of the transcription factor XBP-1 or activation of ATF6 (downstream of XBP-192 
1) in the podocyte of diabetic mice aggravates DN. Of interest, mice with genetically 193 
impaired podocyte insulin signalling exhibited impaired UPR (XBP-1 activation) that 194 
was associated with more severe diabetic kidney disease when compared with 195 
diabetic controls [41]. 196 
 197 
Autophagy, regulated by the mammalian target of rapamycin complex 1 (mTORC1) 198 
is, with the UPR, essential to maintain cellular homeostasis and in the context of ER 199 
stress contributes towards the elimination of toxic and damaged cellular components 200 
[42]. Haploinsufficiency of mTORC1 in podocytes or administration of rapamycin (a 201 
mTORC1 inhibitor) resulting in activation of autophagy [43], has been shown to 202 
prevent progressive DN [44, 45]. In contrast, mTORC1 activation in podocytes, 203 
resulting in inhibition of autophagy, leads to accelerated DN [46]. Loss of insulin 204 
sensitivity in cultured podocytes results in suppression of autophagy and addition of 205 
rapamycin in these cells attenuates insulin resistance [47]. 206 
 207 
 208 
Insulin resistance, the glomerular cell cytoskeleton and other mechanisms 209 
Experiments using podocyte cell lines have begun to reveal other downstream targets 210 
of insulin resistance which may play a role in DN. Addition of exogenous insulin to 211 
human podocytes in culture led to cytoskeletal rearrangement [18], a process which 212 
has been pharmacologically targeted using small molecules as a novel therapy for DN 213 
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[48]. Other studies [49] have identified the cytoskeleton protein septin-7 as playing an 214 
important role in the regulation of insulin-mediated translocation of GLUT4 vesicles to 215 
the plasma membrane and the control of podocyte glucose transport. Insulin may also 216 
modulate calcium signalling in podocytes which has been shown to be important in 217 
maintaining cytoskeletal dynamics by altering the expression of canonical transient 218 
receptor potential-6 channel-TRPC6 [50] and large-conductance Ca(2+)-activated 219 
K(+) channels [51].  220 
 221 
Insulin stimulates the Phosphoinositide 3-kinase (PI3K) pathway and causes AKT 222 
activation. In normal physiology, insulin stimulation of podocytes results in AKT 223 
phosphorylation (activation), while, in insulin-resistant disease settings such as 224 
diabetes, a number of reports have shown an early loss of glomerular AKT 225 
phosphorylation whilst AKT signaling is maintained in the tubular compartment of the 226 
kidney [28].  AKT exists in three isoforms with AKT2 being located specifically in the 227 
podocyte within the kidney [52]. A loss of podocyte AKT2 activation is detrimental 228 
when there is chronic kidney disease associated with nephron loss [52]. AKT2 is the 229 
major isoform through which insulin signals [53]. It is currently not completely clear if 230 
the loss of renal AKT activation is detrimental in the setting of diabetes as a number 231 
of studies have shown an increase in AKT phosphorylation in the vasculature in 232 
experimental animal models of diabetes [54-58], and pharmacological inhibition of the 233 
AKT activation by AS101, may confer renoprotection in diabetes [59]. More work will 234 
have to be performed to dissect the exact role of AKT in diabetic kidney disease. 235 
 236 
Insulin can also modulate the renin-angiotensin-aldosterone system, critical for 237 
regulating glomerular haemodynamics in DN, by increasing the expression and activity 238 
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of angiotensin converting enzyme-2 (ACE2)[60]. Further work is required to identify 239 
other downstream targets of podocyte insulin signalling ideally using systems biology 240 
genomic and proteomic approaches. Candidate molecules altered by insulin signalling 241 
might include recently identified genes found to be associated with the early stages of 242 
albuminuria in in-bred strains of mice [61]. 243 
 244 
 245 
Reactive oxygen species and diabetic nephropathy 246 
Over the last decade, an attractive unifying hypothesis has been put forward to explain 247 
diabetic microvascular complications; specifically it was postulated that an excess in 248 
cellular substrate availability leads to an increase in reactive oxygen species (ROS) 249 
which in turn drives vascular complications in DN [62]. However, this unifying 250 
hypothesis has been challenged by the negative results of antioxidant-based clinical 251 
trials [63], and a new theory of “mitochondrial hormesis” has been proposed [64], 252 
whereby the increased mitochondrial superoxide production is considered an indicator 253 
of healthy mitochondria and physiologic oxidative phosphorylation. 254 
 255 
Recent research has found a reduction of superoxide in the kidneys of streptozotocin 256 
(STZ)-induced diabetic Akita-mice, as assessed by a combination of in vivo real-time 257 
transcutaneous fluorescence, confocal microscopy, and electron paramagnetic 258 
resonance analysis [65]. The authors of this study found that chronic exposure to high 259 
glucose levels (as occurs in diabetes) results in disrupted mitochondria, which was 260 
associated with a reduced respiration and a lowering in mitochondrial superoxide. 261 
Interestingly, genetic or pharmacological correction of mitochondrial dysfunction by 262 
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improving substrate utilisation was recently found to be renoprotective in a mouse 263 
model of tubulointerstitial fibrosis [66].  264 
 265 
From experimental animal studies it appears that increased cytosolic superoxide and 266 
other non-mitochondrial sources of ROS generation play a prominent role in diabetic 267 
kidney disease and that strategies involving a more targeted (towards specific cellular 268 
compartments such as the cytosol) antioxidant approach, may be important to optimize 269 
renoprotection in diabetes [67]. Along these lines, human studies have shown that 270 
leukocytes obtained from patients with diabetes and DN (when compared with non-271 
diabetics or patients with diabetes without DN) have a reduced maximal respiration 272 
and reserve capacity [68, 69] suggesting that chronic metabolic stress in the presence 273 
of a reduced mitochondrial function (being this primary or secondary) will manifest with 274 
low ATP-linked respiration, low reserve capacity and reduced mitochondrial ROS 275 
generation. 276 
 277 
It could be speculated that metabolic stress could initially (early phase) promote an 278 
excess production of mitochondrial superoxide [62] that will lead, in a subsequent 279 
chronic phase (late phase), towards mitochondrial damage, progressive deterioration 280 
in bioenergetic cellular function, reduced ATP synthesis and cell death. Future work 281 
will address these questions, and need to evaluate whether cells are able to maintain 282 
adequate number of healthy mitochondria which can then burn sufficient substrates for 283 
energy production and maintain a “balanced” level of ROS (Figure 2). 284 
 285 
AMP-activated protein kinase (AMPK) is a stress-activated kinase that is activated in 286 
response to depleting ATP to preserve cell survival under conditions of reduced 287 
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substrate utilisation. AMPK activation has been involved in mitochondrial biogenesis 288 
by leading to increased mitochondrial substrate utilisation and ATP generation, in 289 
parallel with stimulation of antioxidant gene expression to ensure an optimal redox 290 
balance [70]. Reduced AMPK, as seen in the diabetic kidney of both rodents and 291 
humans [65], is associated with reduced catabolic activity (mitochondrial function) [65], 292 
and reduced AMPK-mediated inhibition of NADPH oxidase (Nox2) resulting in 293 
increased ROS production [71, 72]. Taken together, these results suggest that, in the 294 
diabetic kidney, upregulation of AMPK could be therapeutically beneficial in DN [73] to 295 
regulate nutrient utilisation and mitochondrial function towards maintenance of an 296 
optimum redox balance. 297 
 298 
Overall, more work is required in the DN field to dissect between these opposing 299 
theories specifically by examining mitochondrial function and specific ROS moieties 300 
both in vitro and in tissues. 301 
 302 
 303 
Vascular endothelial growth factor-A (VEGFA) and the glycocalyx 304 
Recent studies have shown a connection between insulin resistance and the 305 
subsequent production of VEGFA in podocytes [74]. This finding is likely to be 306 
important in the setting of DN with many elegant studies using transgenic mice 307 
highlighting the importance of podocyte VEGFA levels in the progression of this 308 
condition [4]. A new aspect of VEGFA signalling in the glomerulus is potential cross 309 
talk between VEGFA secreted from podocytes and the GECs glycocalyx in the setting 310 
of diabetes. There is clear evidence that the GECs glycocalyx is lost both systemically 311 
and within the diabetic glomerulus, and that this contributes to both cardiovascular and 312 
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renal complications [6]. Mechanistically there are a number of pathways which led to 313 
loss of the glomerular glycocalyx including hyperglycaemia [75], and ROS [76].  314 
 315 
During the early phases of diabetes an increase in VEGFA causes glycocalyx 316 
shedding from the GECs. Furthermore, the inhibitory isoform of VEGFA called VEGF-317 
A165b also plays a role in maintaining the GECs glycocalyx in diabetes. Oltean et al. 318 
[77] have shown that in diabetic patients with progressive nephropathy, the renal 319 
expression of VEGF-A165b is lost. They went on to develop a number of murine models 320 
of DN and have shown that genetic overexpression or pharmacological administration 321 
of VEGF-A165b to the mouse, acting through VEGF receptor 2 in the GECs, restores 322 
damaged glomerular endothelial glycocalyx and improves renal function. VEGF-A165b 323 
also improved the permeability of isolated human diabetic glomeruli suggesting the 324 
response is conserved across murine and human species [77]. 325 
 326 
VEGFA signalling is only one component of a complex system of molecular cross talk 327 
between the podocyte and glycocalyx. New insights have revealed that molecules 328 
produced by the endothelium can signal to the podocyte and then back to the 329 
glomerular glycocalyx. Using transgenic murine models and conditionally immortalised 330 
murine podocytes and GECs, Garsen et al have shown that endothelin-1 (ET-1), an 331 
endothelial derived vasoconstrictor, is released by the GECs in diabetic conditions and 332 
leads to shedding of the glycocalyx [78]. This is prevented by deleting the ET-1 333 
receptor specifically in the podocyte. This is therapeutically intriguing as there are ET-334 
1 receptor antagonists that have been shown to ameliorate early microalbuminuric 335 
diabetic kidney disease [79]. In the future, therapeutic approaches to maintain the 336 
GECs glycocalyx should be explored in more detail (Figure 3). 337 
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 339 
SGLT2 and kidney disease 340 
Poor glycaemic control and hyperinsulinaemia (at least in the early phase of diabetes) 341 
lead to upregulation of SGLT2 expression and proximal tubular SGLT2-mediated 342 
sodium-glucose reabsorption [80], which in turns is believed to also contribute to higher 343 
blood pressure levels [81]. SGLT2 inhibitors have recently been developed as oral 344 
hypoglycaemic agents [82]. The SGLT2 antagonists block the sodium-coupled energy 345 
dependent glucose proximal tubular reabsorption resulting in improvement in diabetes 346 
control, weight loss and blood pressure lowering. Recent clinical trials have 347 
demonstrated a dramatic cardiovascular [83] and renoprotective [84] effect of the 348 
SGLT2 inhibitor empaglifozin. 349 
The mechanism by which SGLT2 inhibitors exert their renoprotective effects is 350 
currently unknown. One possibility is that the improvement in renal disease is 351 
secondary to activation of tubuloglomerular feedback, a prime mechanism that 352 
determines a reduction in glomerular capillary pressure [85]. A complementary 353 
mechanism may be that the inhibition of enhanced tubuli sodium-coupled glucose 354 
transport seen in diabetes would result in diminished tubulointerstitial injury and 355 
progression of DN [81]. The use of SGLT2 inhibitors in combination with inhibitors of 356 
the renin-angiotensin-aldosterone system in patients with diabetes may confer some 357 
renoprotection via upregulation of ACE2 and angiotensin 1-7/ 1-9 [86] which retains a 358 
vasodilatory, anti-proliferative, anti-inflammatory and anti-oxidative stress effect [87].  359 
Inhibition of SGLT2 increased expression and activity in diabetes [85] has been 360 
paralleled by activation of AMPK [88], an could promote a favourable renal outcome.  361 
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In parallel to these “renal mechanisms”, natriuresis and plasma volume contraction 362 
paralleled by blood pressure reduction has been also been proposed as a “systemic” 363 
renoprotective mechanisms for SGLT2 inhibitors [89](Figure 4). 364 
 365 
Concluding Remarks and Future Perspectives  366 
Glomerular cellular insulin resistance plays an important role in mitochondrial 367 
dysfunction-ER stress and the UPR, which contribute to glomerular cell dysfunction 368 
and progressive kidney disease. AMPK, with its important role in mitochondrial 369 
function, could represent a potential target for treatment in DN; more studies are 370 
required to assess the role of AMPK on podocyte biology and the regulation of the 371 
glomerular filtration barrier. A link between the tubular compartment and the 372 
glomerulus is evident in the pathophysiology of tubular SGLT2-mediated Na-coupled 373 
glucose reabsorption in diabetes, however it is not yet completely clear what are the 374 
mechanisms underlying these beneficial effects. Future studies will need to better 375 
dissect the cellular mechanisms underlying the proposed pathways outlined in this 376 
article, specifically focusing on the physiology of the nephron as a whole entity, and 377 
by identifying potentially targetable molecules for future treatment.   378 
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TABLE 1  394 
Diabetes results in inflammation, increased adiposity and chronic hyperglycaemia 395 
which drive podocyte insulin resistance resulting in disruption to podocytes and the 396 
glomerulus.  (NOD2: Nucleotide-binding oligomerization domain containing protein 2, 397 
TLR: Toll-like receptor, SMAD: vertebrate homologues of Sma and Mad; FFAs: free 398 
fatty acids; SHP-1: Src homology-2 domain-containing phos- phatase-1) 399 
 400 
Diabetes related 
phenotypes 
Molecular 
mechanisms Glomerular phenotype REF # 
Chronic 
inflammation 
Increased NOD2 
Increased pro-
inflammatory responses 
and impaired insulin 
signaling 
 [22] 
Increased TLR Podocyte inflammation 
and insulin resistance    [23] 
Increased SMAD 
Mitochondrial 
dysfunction and insulin 
resistance in podocytes 
    [21] 
Obesity 
Decreased 
adiponectin 
Albuminuria and 
increased oxidative 
stress in podocytes 
    [24] 
Increased FFAs 
Inhibition of insulin-
stimulated glucose 
uptake in human 
podocytes 
    [26] 
Elevated blood 
sugar 
Increased SHP-1 
Podocyte insulin 
resistance and 
detachment 
     [27] 
Ubiquitination and 
degradation of 
components of insulin 
signaling pathway  
Diabetic glomerulopathy 
and albuminuria      [28] 
 401 
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Figure legends: 402 
 403 
Figure 1: Schematic structure of a normal and diabetic glomeruli.  404 
(A) Schematic representation of a normal glomerular structure. (B) The major 405 
glomerular structural changes occurring in diabetic glomerulopathy. Note the 406 
extensive mesangial expansion, the thickening of the glomerular basement membrane 407 
(GBM), the detachment of podocyte, and the impairment in the glycocalyx and 408 
glomerular endothelial cells (GECs). 409 
 410 
Figure 2: Hypothetical shift of superoxide level imbalance in diabetic 411 
complications. 412 
Acute (early phase) exposure of cells to elevated glucose levels results in upregulation 413 
of glucose oxidation with pyruvate-mediated stimulation of the tricarboxylic acid (TCA) 414 
cycle with increased production of electron donors (NADH, FADH2) that, via the 415 
electron transport chain, will results in an excess generation of superoxide (O2-). Cells 416 
chronically exposed to elevated glucose levels (late phase) will result in reduction in 417 
the availability of acetyl-CoA (secondary to inhibition of pyruvate dehydrogenase 418 
activity) for the mitochondria resulting in reduced electron transport chain activity, a 419 
fall in mitochondrial ATP production, less mitochondria superoxide production and 420 
cellular dysfunction. 421 
 422 
Figure 3: Glomerular cell cross-talk and glycocalyx.  423 
Transmission electron microscopy image of the glomerular filtration barrier (podocyte 424 
glomerular basement membrane (GBM), glomerular endothelial cells (GEC), and 425 
glycocalyx) highlighting how molecules produced by the podocytes and endothelium 426 
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(via the podocyte) can signal to the glomerular glycocalyx. Recently identified key 427 
molecules such as VEGF-A165b, VEGF-C, and angiopoietin-1 (ANGPT1) confer a 428 
beneficial effect (green arrows) towards glycocalyx maintenance. Conversely VEGF-429 
A165 and Endothelin (secreted by GECs and signals to the Endothelin-1 receptor in the 430 
podocyte causing this cell to release heparanase, which then acts on the glomerular 431 
glycocalyx to cleave heparin sulphate) promote shedding of the GECs glycocalyx (red 432 
arrows).  433 
 434 
Figure 4: Proposed SGLT2 inhibition-mediated renoprotective mechanisms. 435 
SGLT2 inhibition blocks sodium-glucose coupled glucose reabsorption at the S1 S2 436 
segment of the proximal tubule. The net result is loss of glucose and sodium (the latter 437 
especially in patients on renin angiotensin aldosterone blockade) in the urine, with 438 
secondary weight loss, improvement in glycaemic control, blood pressure fall, and 439 
plasma volume contraction. These effects confer cardiac and renal protection in 440 
patients with diabetes. (ACE2: angiotensin converting enzyme 2) 441 
  442 
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OUTSTANDING QUESTIONS BOX 
 
- What are the main pathway/s that link insulin action, mitochondrial function and UPR? 
- What are the mitochondrial-driven mechanisms that predispose towards faster kidney 
disease progression in diabetes? Is there an alteration in the mitochondria driven UPR-
mediated response towards cell survival or is it a primary alteration in UPR response?  
- Does AMPK, with its important role as a regulator of nutrient utilisation and mitochondrial 
function, represent a real answer to diabetes mediated ER-stress mitochondria 
dysfunction, UPR, and, if so, what are the mechanisms? 
- Could targeting the glycocalyx be a new therapeutic approach for diabetic nephropathy? 
What are the important molecular signals from the podocyte and endothelium which 
regulate the glycocalyx? 
- How does SGLT2 inhibition confer reno-protection? Is it about SGLT2-driven sodium and 
volume loss (systemic effect) or tubuloglomerular feedback and inflammation (intrarenal 
effect)? Are these mechanisms behind the renoprotective effects of these drugs? 
 
 
TRENDS BOX: 
- Insulin resistance is a key mechanism for diabetic glomerulopathy. 
- Disruption in the molecular communication between glomerular podocytes and endothelia 
is critical in the progression of diabetic nephropathy. 
- Raised (but not too elevated) mitochondrial superoxide cellular levels in parallel with 
healthy mitochondria are protective against progression of diabetic kidney disease. 
- A reduction in maximal mitochondrial respiration and reserve capacity could represent an 
important driving force for kidney disease progression in diabetes. 
- Inhibition of SGLT2-mediated sodium-coupled glucose transport confers renoprotection of 
similar magnitude of inhibitors of the renin-angiotensin-aldosterone system. 
 
 
